Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan

Published:2014-12 Issue: Volume:17 Page:9-19
ISSN:1756-1841
Container-title:International Journal of Rheumatic Diseases
language:en
Short-container-title:Int J Rheum Dis

Author:

Chiu Ying-Ming¹²,Lang Hui-Chu³,Lin Hsiao-Yi⁴,Yang Ming-Ta⁵⁶,Fang Chi-Hui⁷⁸,Yang Ya-Wen⁷⁸,Schabert Vernon F.⁹,Tang Boxiong⁷⁸

Affiliation:

1. Division of Allergy Immunology & Rheumatology; Changhua Christian Hospital; Changhua Taiwan

2. Department of Nursing; College of Medicine & Nursing; HungKuang University; Taichung Taiwan

3. Institute of Hospital and Health Care Administration; National Yang-Ming University; Taipei Taiwan

4. Division of Allergy, Immunology and Rheumatology; Department of Medicine; Veterans General Hospital; Taipei Taiwan

5. IMS Health; Taipei Taiwan

6. IMS Health; New York New York USA

7. Pfizer Inc.; Taipei Taiwan

8. Pfizer Inc.; New York New York USA

9. IMS Health; Woodland Hills California USA

Publisher

Wiley

Subject

Rheumatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1756-185X.12539/fullpdf

Reference43 articles.

1. New therapies for treatment of rheumatoid arthritis;Smolen;Lancet,2007

2. National Institute for Health and Clinical Excellence 2010 Rheumatoid Arthritis http://guidance.nice.org.uk/CG79Guidance/

3. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis;Saag;Arthritis Rheum,2008

4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs;Smolen;Ann Rheum Dis,2010

5. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial;Keystone;Arthritis Rheum,2004

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis;Expert Opinion on Drug Safety;2024-05-23

2. Development of a nursing practice scale for rheumatoid arthritis treatment with biological disease-modifying anti-rheumatic drugs;Modern Rheumatology;2023-06-21

3. Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries;Arthritis Research & Therapy;2023-06-12

4. Regional risk of tuberculosis and viral hepatitis with tumor necrosis factor-alpha inhibitor treatment: A systematic review;Frontiers in Pharmacology;2023-01-20

5. Incidence of severe infection in patients with rheumatoid arthritis taking biologic agents: a systematic review;JBI Evidence Synthesis;2023-01-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3